This study argues for "clinicaltrial re-innovation," highlighting new designs like basket, umbrella, and platform trials that incorporate biomarker technologies to meet the dynamic needs of precision medicine, potentially enabling more effective, patient-specific treatments and overcoming limitations of traditional disease-centered trials.
This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.
This study found that 5% minoxidil topical foam used once daily for 24 weeks was well tolerated and significantly improved hair regrowth and scalp coverage in women with female pattern hair loss compared to vehicle foam.
This study demonstrated that while the proposed placebo microneedle stamp design was partially successful in blinding participants with low skin sensitivity, further development of suitable placebo controls is needed.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
Han Bio plans to start Phase 1 clinicaltrials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.
A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinicaltrials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
What do clinicaltrials say about the safety and effectiveness of SCUBE3 for hair regrowth?No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
Are there any clinical studies supporting follistatin as a hair loss treatment?There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.
Can centella improve scalp blood flow and thicken hair? What the evidence saysThere is no clinical trial of centella asiatica for hair loss and no study measuring scalp blood flow in people using it; the only hair-related evidence is a 2017 cell-culture study. Centella products are cosmetics that may soothe an irritated scalp, and the link between scalp circulation and pattern hair loss is itself unproven.
Can I use clascoterone if I'm undergoing gender-affirming hormone therapy?No published clinical trial has tested clascoterone in people on gender-affirming hormone therapy, so its safety in that group is unknown. The FDA label reports low systemic exposure and no described effect on blood testosterone, but it also records HPA-axis suppression and raised potassium in a small minority of subjects.